JP2009517403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517403A5 JP2009517403A5 JP2008542534A JP2008542534A JP2009517403A5 JP 2009517403 A5 JP2009517403 A5 JP 2009517403A5 JP 2008542534 A JP2008542534 A JP 2008542534A JP 2008542534 A JP2008542534 A JP 2008542534A JP 2009517403 A5 JP2009517403 A5 JP 2009517403A5
- Authority
- JP
- Japan
- Prior art keywords
- parp
- analog
- inhibitor
- composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73953605P | 2005-11-25 | 2005-11-25 | |
| PCT/US2006/061254 WO2007062413A2 (en) | 2005-11-25 | 2006-11-27 | Use of parp-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009517403A JP2009517403A (ja) | 2009-04-30 |
| JP2009517403A5 true JP2009517403A5 (enExample) | 2010-01-14 |
Family
ID=38068066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542534A Pending JP2009517403A (ja) | 2005-11-25 | 2006-11-27 | Ｐａｒｐ−１阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090170860A1 (enExample) |
| EP (1) | EP1962843B1 (enExample) |
| JP (1) | JP2009517403A (enExample) |
| AT (1) | ATE499098T1 (enExample) |
| AU (1) | AU2006318226A1 (enExample) |
| CA (1) | CA2630900A1 (enExample) |
| DE (1) | DE602006020335D1 (enExample) |
| ES (1) | ES2361566T3 (enExample) |
| WO (1) | WO2007062413A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| JP2007511509A (ja) * | 2003-11-14 | 2007-05-10 | ファルマ・マール・ソシエダード・アノニマ | Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法 |
| RS50822B (sr) * | 2004-10-26 | 2010-08-31 | Pharma Mar S.A., Sociedad Unipersonal | Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743 |
| KR101188691B1 (ko) * | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US9486449B2 (en) | 2007-10-09 | 2016-11-08 | Malka COHEN-ARMON | Cancer therapy |
| WO2009047752A1 (en) * | 2007-10-09 | 2009-04-16 | Ramot At Tel-Aviv University Ltd. | Breast cancer therapy |
| WO2009050303A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for et-743 treatment |
| WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| US9359367B2 (en) | 2012-07-09 | 2016-06-07 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
| MX2015006780A (es) | 2012-12-31 | 2015-08-06 | Cadila Healthcare Ltd | Derivados de ftalazin-1-(2h)-ona sustituida. |
| CN106853252B (zh) * | 2015-12-09 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | 曲贝替定药物组合物及其制备方法 |
| WO2017181918A1 (zh) * | 2016-04-18 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的酞嗪酮化合物及其药物组合物 |
| KR20180097876A (ko) * | 2017-02-24 | 2018-09-03 | 주식회사 온코크로스 | 1,5-이소퀴놀린디올을 포함하는 피부 노화 방지 및 주름 개선용 조성물 |
| LT3615544T (lt) | 2017-04-27 | 2023-05-10 | Pharma Mar S.A. | Priešnavikiniai junginiai |
| EP3960177A1 (en) * | 2020-08-26 | 2022-03-02 | Anturec Pharmaceuticals GmbH | Composition comprising ttf-ngr for use in treating soft-tissue sarcoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| EP1633362B1 (en) * | 2003-05-28 | 2012-09-26 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20050187172A1 (en) * | 2003-12-23 | 2005-08-25 | Masferrer Jaime L. | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
-
2006
- 2006-11-27 JP JP2008542534A patent/JP2009517403A/ja active Pending
- 2006-11-27 ES ES06840026T patent/ES2361566T3/es active Active
- 2006-11-27 WO PCT/US2006/061254 patent/WO2007062413A2/en not_active Ceased
- 2006-11-27 CA CA002630900A patent/CA2630900A1/en not_active Abandoned
- 2006-11-27 US US12/094,744 patent/US20090170860A1/en not_active Abandoned
- 2006-11-27 AT AT06840026T patent/ATE499098T1/de not_active IP Right Cessation
- 2006-11-27 AU AU2006318226A patent/AU2006318226A1/en not_active Abandoned
- 2006-11-27 DE DE602006020335T patent/DE602006020335D1/de active Active
- 2006-11-27 EP EP06840026A patent/EP1962843B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160067241A1 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions | |
| KR20160061911A (ko) | 최적하 투여된 화학 화합물의 치료 효과 | |
| JP2009510171A5 (enExample) | ||
| US20080255171A1 (en) | Combination of Nilotinib with Farnesyl Transferase Inhibitors | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| ES2361566T3 (es) | Uso de inhibidores de parp-1. | |
| WO2017042634A2 (en) | Use of dianhydrogalactitol or derivatives and analogs thereof for treatment of non-small-cell lung carcinoma, glioblastoma, and ovarian carcinoma by induction of dna damage and stalling of cell cycle | |
| TW201605450A (zh) | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 | |
| JP2024528725A (ja) | Ｐａｒｐ阻害剤及びアシルフルベンの併用によるがんの治療 | |
| US20130197017A1 (en) | Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-11g | |
| US8653093B2 (en) | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases | |
| JP2008545796A (ja) | アミノピリミジンキナーゼモジュレーターを用いたｆｌｔ３キナーゼの相乗的モジュレーション | |
| JP2008543771A (ja) | アミノピリミジンキナーゼモジュレーターを用いたｆｌｔ３キナーゼの相乗的モジュレーション | |
| EP2007391B1 (en) | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor | |
| JP2008501007A (ja) | 異常な細胞増殖を治療するための方法 | |
| AU2011202833B2 (en) | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor |